Open AccessFosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
Author(s) -
Patrick Langford
Publication year - 2010
Publication title -
core evidence
Language(s) - English
Resource type - Journals
eISSN - 1555-175X
pISSN - 1555-1741
DOI - 10.2147/ce.s6012
Subject(s) - aprepitant , medicine , chemotherapy induced nausea and vomiting , nausea , vomiting , ondansetron , chemotherapy , oncology , anesthesia , antiemetic
The selective neurokinin-1 receptor antagonist aprepitant is effective in the treatment of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with both moderately and highly emetogenic chemotherapy. Fosaprepitant has been developed as an intravenous prodrug of aprepitant.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom